Still confused about PrEP? Don’t know what to make of the controversy surrounding it?
Sign up for next week’s webinar!
In response to recent news from the FDA regarding the use of the drug Truvada for prevention, Mapping Pathways, AIDS United and the AIDS Foundation of Chicago are presenting a webinar focusing on the ARV-based strategy PrEP (pre-exposure prophylaxis.)
Please join us on Tuesday, June 19th at 3:00 pm EST for this webinar by emailing [email protected] to register.
On May 10, the FDA Antiviral Drug Advisory Committee strongly recommended that emtricitabine/tenofovir disoproxil fumarate (TDF/FTC or Truvada) be approved for use as pre-exposure prophylaxis (PrEP) among sexually active adult men and women – particularly gay men and other MSM, serodiscordant heterosexual couples, and other individuals at high risk. It is likely the FDA will follow the committee’s recommendations and issue a new prevention indication for the use of Truvada by mid-September.
While doctors have been able to prescribe Truvada “off label” for the prevention of HIV, this new indication will make it official – and allow for greater access.
